Zynerba Pharma (ZYNE) Misses Q4 EPS by 33c

Zynerba Pharma (NASDAQ: ZYNE) reported Q4 EPS of ($0.62), $0.33 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $49.28 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Zynerba Pharma (ZYNE) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c
• Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS) Tops Q2 EPS by 24c